The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Basit Öğe Kaydı
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridGürbüz, Mustafa/0000-0001-7680-4142
dc.authoridDemiray, Aydın/0000-0002-3343-0184
dc.authoridDemirkıran, Aykut/0000-0002-2842-4695
dc.authoridGürbüz, Mustafa/0000-0001-7680-4142
dc.authoridgülmez, ahmet/0000-0002-3353-344X
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidGürbüz, Mustafa/JAN-6390-2023
dc.authorwosidCaner, Burcu/AAE-8549-2022
dc.authorwosidDemiray, Aydın/AEN-1780-2022
dc.authorwosidYumuk, Perran Fulden/A-6189-2018
dc.authorwosidDemirkıran, Aykut/HKN-0171-2023
dc.authorwosidGürbüz, Mustafa/CAJ-3354-2022
dc.contributor.authorHizal, Mutlu
dc.contributor.authorBilgin, Burak
dc.contributor.authorPaksoy, Nail
dc.contributor.authorAcikgoz, Ozgur
dc.contributor.authorSezer, Ahmet
dc.contributor.authorGurbuz, Mustafa
dc.contributor.authorAk, Naziye
dc.date.accessioned2024-08-04T20:50:28Z
dc.date.available2024-08-04T20:50:28Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile.en_US
dc.identifier.doi10.1007/s00432-021-03748-7
dc.identifier.endpage1508en_US
dc.identifier.issn0171-5216
dc.identifier.issn1432-1335
dc.identifier.issue6en_US
dc.identifier.pmid34331582en_US
dc.identifier.scopus2-s2.0-85111543488en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1501en_US
dc.identifier.urihttps://doi.org/10.1007/s00432-021-03748-7
dc.identifier.urihttps://hdl.handle.net/11616/100081
dc.identifier.volume148en_US
dc.identifier.wosWOS:000679766900001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectOsimertiniben_US
dc.subjectNon-small cell lung canceren_US
dc.subjectEGFRen_US
dc.subjectT790Men_US
dc.subjectSecond lineen_US
dc.titleThe real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu